viewSativa Group PLC

Sativa granted controlled drug licence by UK Home Office to grow high-THC cannabis

The firm said it would now begin a partnership with King's College London to research the effects of cannabinoids on inflammation and respiratory conditions

Sativa Group PLC - Sativa granted controlled drug licence by UK Home Office to grow cannabis
The licence allows Sativa to grow cannabis plants that contain more than 0.2% THC

Sativa Group PLC (LON:SATI) has received a controlled drug licence from the UK Home Office, allowing it to produce and supply cannabis at its headquarters in Somerset.

The medicinal cannabis firm said it will immediately begin a research partnership agreement with King’s College London to research the impact of cannabinoids on inflammation and respiratory conditions.

READ: Sativa Group revenues climb as CBD moves mainstream

The licence allows the company to produce cannabis plants that contain more than 0.2% tetrahydrocannabinol (THC), the main psychoactive compound in cannabis.

Sativa already has a licence for the production of low-THC cannabis, also known as hemp, which was granted in February 2018.

Plants used in the research partnership will be grown at Sativa’s facility before being dried to allow cannabinoids to be extracted for use in KCL’s labs.

"We are delighted to receive this licence, responding to calls from regulators, government and healthcare providers for further research and development into the efficacy of medicinal cannabis”, said Sativa chief executive Henry Lees-Buckley.

“We are committed to operating at these high standards and to partner with Kings College London, to help establish a clinical pathway for patients to access medicinal cannabis", he added.

Quick facts: Sativa Group PLC

Price: 2.93 GBX

Market: AQSE
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sativa Group PLC named herein, including the promotion by the Company of Sativa Group PLC in any Content on the Site, the Company receives from...



Sativa Investments PLC acquires UK-based PhytoVista Laboratories

Geremy Thomas, chief executive of Sativa Investments PLC (AQSE:SATI), tells Proactive's Andrew Scott they've agreed to buy PhytoVista Laboratories, a UK-based lab that tests cannabis oils and hemp products, for £435,000. The British medicinal cannabis investment vehicle will pay £235,000...

on 4/7/18

2 min read